BACKGROUND: Acute respiratory tract infection (ARTI) is the most common reason for antibiotic prescription in adults. Antibiotics are often inappropriately prescribed for patients with ARTI. This article presents best practices for antibiotic use in healthy adults (those without chronic lung disease or immunocompromising conditions) presenting with ARTI. METHODS: A narrative literature review of evidence about appropriate antibiotic use for ARTI in adults was conducted. The most recent clinical guidelines from professional societies were complemented by meta-analyses, systematic reviews, and randomized clinical trials. To identify evidence-based articles, the Cochrane Library, PubMed, MEDLINE, and EMBASE were searched through September 2015 using the following Medical Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinusitis," and "the common cold." HIGH-VALUE CARE ADVICE 1: Clinicians should not perform testing or initiate antibiotic therapy in patients with bronchitis unless pneumonia is suspected. HIGH-VALUE CARE ADVICE 2: Clinicians should test patients with symptoms suggestive of group A streptococcal pharyngitis (for example, persistent fevers, anterior cervical adenitis, and tonsillopharyngeal exudates or other appropriate combination of symptoms) by rapid antigen detection test and/or culture for group A Streptococcus. Clinicians should treat patients with antibiotics only if they have confirmed streptococcal pharyngitis. HIGH-VALUE CARE ADVICE 3: Clinicians should reserve antibiotic treatment for acute rhinosinusitis for patients with persistent symptoms for more than 10 days, onset of severe symptoms or signs of high fever (>39 °C) and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or onset of worsening symptoms following a typical viral illness that lasted 5 days that was initially improving (double sickening). HIGH-VALUE CARE ADVICE 4: Clinicians should not prescribe antibiotics for patients with the common cold.
BACKGROUND: Acute respiratory tract infection (ARTI) is the most common reason for antibiotic prescription in adults. Antibiotics are often inappropriately prescribed for patients with ARTI. This article presents best practices for antibiotic use in healthy adults (those without chronic lung disease or immunocompromising conditions) presenting with ARTI. METHODS: A narrative literature review of evidence about appropriate antibiotic use for ARTI in adults was conducted. The most recent clinical guidelines from professional societies were complemented by meta-analyses, systematic reviews, and randomized clinical trials. To identify evidence-based articles, the Cochrane Library, PubMed, MEDLINE, and EMBASE were searched through September 2015 using the following Medical Subject Headings terms: "acute bronchitis," "respiratory tract infection," "pharyngitis," "rhinosinusitis," and "the common cold." HIGH-VALUE CARE ADVICE 1: Clinicians should not perform testing or initiate antibiotic therapy in patients with bronchitis unless pneumonia is suspected. HIGH-VALUE CARE ADVICE 2: Clinicians should test patients with symptoms suggestive of group A streptococcal pharyngitis (for example, persistent fevers, anterior cervical adenitis, and tonsillopharyngeal exudates or other appropriate combination of symptoms) by rapid antigen detection test and/or culture for group A Streptococcus. Clinicians should treat patients with antibiotics only if they have confirmed streptococcal pharyngitis. HIGH-VALUE CARE ADVICE 3: Clinicians should reserve antibiotic treatment for acute rhinosinusitis for patients with persistent symptoms for more than 10 days, onset of severe symptoms or signs of high fever (>39 °C) and purulent nasal discharge or facial pain lasting for at least 3 consecutive days, or onset of worsening symptoms following a typical viral illness that lasted 5 days that was initially improving (double sickening). HIGH-VALUE CARE ADVICE 4: Clinicians should not prescribe antibiotics for patients with the common cold.
Authors: Derek N Bremmer; Briana E DiSilvio; Crystal Hammer; Moeezullah Beg; Swati Vishwanathan; Daniel Speredelozzi; Matthew A Moffa; Kurt Hu; Rasha Abdulmassih; Jina T Makadia; Rikinder Sandhu; Mouhib Naddour; Noreen H Chan-Tompkins; Tamara L Trienski; Courtney Watson; Terrence J Obringer; Jim Kuzyck; Thomas L Walsh Journal: J Gen Intern Med Date: 2018-02-05 Impact factor: 5.128
Authors: Katherine M Shea; Athena L V Hobbs; Theresa C Jaso; Jack D Bissett; Christopher M Cruz; Elizabeth T Douglass; Kevin W Garey Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Nathan R Shively; Deanna J Buehrle; Marilyn M Wagener; Cornelius J Clancy; Brooke K Decker Journal: Antimicrob Agents Chemother Date: 2019-12-20 Impact factor: 5.191
Authors: Aditi Patel; Elizabeth R Pfoh; Anita D Misra Hebert; Alexander Chaitoff; Aryeh Shapiro; Niyati Gupta; Michael B Rothberg Journal: J Gen Intern Med Date: 2019-10-19 Impact factor: 5.128
Authors: Malaika Schwartz; Victoria Hardy; Gina A Keppel; William Alto; Jaime Hornecker; Beth Robitaille; Jon Neher; John Holmes; M Ashworth Dirac; Allison M Cole; Matthew Thompson Journal: J Am Board Fam Med Date: 2017 Sep-Oct Impact factor: 2.657
Authors: Sarah Kabbani; Adam L Hersh; Daniel J Shapiro; Katherine E Fleming-Dutra; Andrew T Pavia; Lauri A Hicks Journal: Clin Infect Dis Date: 2018-06-18 Impact factor: 9.079